CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits [Yahoo! Finance]
CVRx, Inc. (CVRX)
Company Research
Source: Yahoo! Finance
This includes the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight the long-term sustained benefits of Barostim in heart failure (HF) patients with reduced ejection fraction. It should be noted that BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April 2016 to develop scientific evidence for the safety and effectiveness of Baroreflex Activation Therapy with Barostim. The manuscript is available online at the European Journal of Heart Failure website. CVRx had previously announced some of these data as part of expanded labeling granted by the FDA on Dec 23, 2023. Also, two new post-hoc analyses of the BeAT-HF trial data, presented last month at Technology in Heart Failure Therapeutics (THT) 2024, suggest additional important benefits of Barostim. The latest availability of additional data supporting the long-term benefits of Barostim is a major stepping stone fo
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRXGlobeNewswire
- CVRx First Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]Yahoo! Finance
- CVRx, Inc. (NASDAQ: CVRX) had its price target lowered by analysts at Lake Street Capital from $35.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Investigation Into CVRx, Inc. (CVRX) Announced by Holzer & Holzer, LLCGlobeNewswire
- CVRx, Inc. (NASDAQ: CVRX) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $32.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
CVRX
Earnings
- 4/30/24 - Miss
CVRX
Sec Filings
- 4/30/24 - Form 8-K
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- CVRX's page on the SEC website